What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Pimitespib will be administered orally in 5 consecutive days followed by 2 days off treatment (QD 5) on an empty stomach at least 1 hour before or 2 hours after a meal. The doses in the Dose Escalation Part will be 80, 120 (starting dose), and 160 mg. The doses used in Arm A will be MTD or recommended dose (RD) based on the information, including the safety and the pharmacokinetics (PK) data in…”In the company’s words, NCT05245968 on ClinicalTrials.gov
- Tested for
- Gastrointestinal Stromal Tumors, Advanced or Metastatic Solid Tumor, Pancreatic Ductal Adenocarcinoma, Colorectal Cancer, Non-small Cell Lung Cancer, Gastric Cancer, Alveolar Soft Part Sarcoma, Esophageal Cancer and 2 more
- Main trialPhase 1
- “This study consists of Dose escalation part and Expansion part. In Dose Escalation Part, the maximum tolerated dose of combination of pimitespib and imatinib in patients with gastrointestinal stromal tumors (GIST) who are judged to be refractory to imatinib, estimate the recommended dose, evaluate safety and pharmacokinetics, and observe the antitumor effect. Expansion part consists of 3 arms. In Arm A, the efficacy and safety will be evaluated, which of the combination of pimitespib and imatinib in patients with GIST who have failed imatinib at doses below the MTD determined in Dose…”In the company’s words, NCT05245968 on ClinicalTrials.gov
- Other names
- TAS-116
Other drugs for Gastrointestinal Stromal Tumors
- RipretinibDeciphera Pharmaceuticals, LLC · Phase 3
- VelzatinibGSK · Phase 3
- NB003Ningbo Newbay Technology Development Co., Ltd · Phase 2/3
- BezuclastinibCogent Biosciences, Inc. · Phase 3
- InlexisertibDeciphera Pharmaceuticals, LLC · Phase 1/2
- KQB198Kumquat Biosciences Inc. · Phase 2
Coming up2
- DecPhase 1 trial completes · ClinicalTrials.gov
- Jun 2027Phase 1 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials3
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Active, not recruiting | Dec 2026 | A Study of Pimitespib in Combination With Imatinib in Patients With GIST (CHAPTER-GIST-101) | |
| Phase 1Recruiting | Jun 2027 | AB122 Platform Study | |
| Phase 1Completed | 3 May 2019 | A Study of TAS-116 in Patients With Solid Tumors |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026